BioNTech SE

BioNTech SE is a global biopharmaceutical manufacturer headquartered in Mainz, Germany, specializing in mRNA-based vaccines and novel immunotherapies for oncology and infectious diseases. The biotechnology company develops personalized mRNA cancer immunotherapies, bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor T-cell therapies. Operating advanced cGMP manufacturing facilities and modular BioNTainer units, BioNTech produces clinical and commercial-scale mRNA products worldwide. The organization serves healthcare providers, governments, and pharmaceutical partners across Europe, North America, Asia, Australia, and Africa. In addition to its flagship COVID-19 mRNA vaccine, BioNTech advances clinical trials for targeted oncology treatments addressing solid tumors, adjuvant cancer care, and infectious disease preventatives. The company integrates deep genomics, artificial intelligence, and bioinformatics tools to accelerate translational drug discovery and precision medicine. Through strategic collaborations with major pharmaceutical firms like Genentech, Bristol Myers Squibb, and Duality Biologics, BioNTech expands its global clinical development pipeline. Headquartered at An der Goldgrube 12 in Mainz, BioNTech conducts research, clinical testing, and biopharmaceutical manufacturing on a global scale.